Pantoprazole

Proton pump inhibitors

ATC code: A02BC02 (Pantoprazole)

Mechanism of action

Irreversibly inhibits H+/K+-ATPase (proton pump) in gastric parietal cells. Same mechanism as omeprazole. A distinctive feature of pantoprazole is its weaker CYP2C19 inhibition. This underpinned the 2009 caution about omeprazole–clopidogrel interaction, but the clinical relevance has been refuted by the COGENT RCT (Bhatt DL et al. NEJM 2010) and subsequent studies: no difference in cardiovascular outcomes between DAPT patients on different PPIs. Pantoprazole remains a reasonable choice in clopidogrel-treated patients, but this is no longer a critical advantage.

Indications

Gastroesophageal reflux disease

First line

First-line GERD therapy. PPIs are the most effective agents for acid suppression. Pantoprazole 40 mg once daily 30 minutes before breakfast. Course 4–8 weeks, then attempt dose reduction or on-demand dosing.

Sources

NSAID gastropathy prophylaxis

First line

First-line prophylaxis of gastropathy in patients on long-term NSAIDs with risk factors – age over 65, ulcer history, concomitant anticoagulants or corticosteroids. Pantoprazole 20 mg once daily for the duration of NSAID therapy.

Sources

Peptic ulcer disease

First line

First-line for peptic ulcer disease. Duodenal ulcer course is 4 weeks, gastric ulcer 8 weeks. In H. pylori eradication, any PPI at double dose twice daily. Pantoprazole is preferred in patients on clopidogrel after coronary stenting.

Sources

Marketing claims without evidence base

The drug is promoted for these uses outside international guidelines. Each entry below is analyzed against AEMPS, FDA, EMA, Cochrane and major RCTs.

PPI for NSAID gastric prophylaxis in low-risk patients

Not recommended

Pantoprazole is a proton pump inhibitor (PPI). It is prescribed for GERD, peptic ulcer, Helicobacter pylori eradication, and gastroprotection with NSAID use in patients at high GI bleeding risk – age over 65, ulcer history, concomitant anticoagulants or corticosteroids ( 2022, 2020). In low-GI-bleeding-risk patients on short-term NSAIDs, routine PPI gastroprotection is not justified: long-term PPI use is linked to specific risks – vitamin B12 and magnesium deficiency, elevated risk of intestinal infections (Clostridioides difficile), pneumonia, hip and vertebral fractures (via impaired calcium absorption), and chronic kidney disease. If pantoprazole was prescribed for long-term use without confirmed high GI risk, consider seeking a second opinion.

Sources

Practical notes

Timing and administration

Take 30 minutes before the first meal. The proton pump is activated by meal-stimulated signaling, and the drug needs to be circulating at that point. Swallow the tablet whole, do not crush – the enteric coating protects against degradation in gastric acid.

Special situations

In vitro, pantoprazole is a weaker CYP2C19 inhibitor than omeprazole or esomeprazole. This was the historical basis of the 's 2009 caution on the clopidogrel interaction, but the COGENT RCT (Bhatt DL et al. NEJM 2010) and subsequent studies have shown no clinically meaningful difference in cardiovascular outcomes between PPIs in DAPT patients. Current position: PPIs are indicated during dual antiplatelet therapy to reduce GI bleeding; the choice of molecule is not critical. Pantoprazole remains a convenient option in clopidogrel-treated patients, especially when other CYP2C19-sensitive drugs are involved.

Drug–drug interactions

3 pairs found. Sorted from critical to minor.

Major

Methotrexate

Antimetabolites, folic acid analogues

Mechanism

Proton pump inhibitors block the renal BCRP transporter, reducing methotrexate clearance. At high oncologic doses: risk of severe delayed toxicity.

Symptoms

Mouth ulcers (mucositis), nausea, diarrhoea, hair loss. Blood counts fall: leukocytes, platelets, erythrocytes. Severe cases: fatal pancytopenia, nephrotoxicity.

Management

At oncologic methotrexate doses, stop pantoprazole 5 days before and resume 5 days after dosing. Alternative: famotidine (H2-blocker, no BCRP effect). At low rheumatologic doses, pantoprazole is acceptable.

Sources

FDA: Methotrexate Sodium Tablets prescribing information (2016)

Pair details →

Moderate

Atorvastatin

HMG-CoA reductase inhibitors (statins)

Mechanism

Pantoprazole is the most CYP-neutral PPI. No clinically significant interaction with statins.

Symptoms

No changes.

Management

The combination is acceptable without dose change. Pantoprazole is the preferred PPI in patients on statins and other CYP3A4-dependent drugs.

Sources

FDA: Lipitor (atorvastatin) prescribing information (2017)

Pair details →

Moderate

Cyanocobalamin

Vitamins. Haemopoietic stimulants

Mechanism

Pantoprazole reduces gastric acidity and B12 release from food. With long-term therapy, B12 deficiency risk is reported, similar to other PPIs.

Symptoms

Fatigue, pallor, paraesthesias in hands and feet, gait instability, memory decline. Develops over 2–4 years of unrecognised therapy.

Management

On long-term pantoprazole (over 2 years), check B12 yearly. Cyanocobalamin can be given regardless of acidity (passive diffusion absorption at high doses). For sustained acid suppression, consider dose reduction or periodic breaks.

Sources

PubMed: Metformin use and vitamin B12 deficiency: a systematic review and meta-analysis (2020)

Pair details →

Check interaction with another drug

Opens the checker prefilled with this drug. Pick the second one from your regimen.

Open checker

Official sources

Direct links to regulator labels. Open in a new tab.

AEMPS / CIMA

Spanish Medicines Information Centre (CIMA)

Label dated: 06/26/2025

EMA

European Medicines Agency

Label dated: 06/12/2009

FDA / DailyMed

FDA — DailyMed Drug Labels

Label dated: 02/03/2025

Safety

Contraindications

Hypersensitivity to PPIs

Serious adverse effects

Clostridioides difficile-associated diarrhea
Hypomagnesemia with long-term use (over 1 year)
Increased fracture risk with long-term use – hip, wrist, spine
Vitamin B12 deficiency with use over 2 years
Acute interstitial nephritis (rare)

Common adverse effects

Headache
Diarrhea
Nausea
Flatulence
Abdominal pain

PregnancyFDA B

FDA category B. Safety data in pregnancy are limited, but animal studies have shown no teratogenic effect. Used when clearly indicated.

Breastfeeding

Compatible. Hale L2. Transfers into milk in small amounts (RID about 1%); infant gastric acid inactivates the molecule before meaningful systemic absorption. AEG and AAP consider it compatible; a nursing mother on reflux or ulcer therapy can continue breastfeeding. The infant may show mild functional gut symptoms (flatulence, stool changes) that usually resolve on their own.

Calculate RID Full profile on NIH LactMed ↗

Reference information, not a clinical decision. Discuss feeding pauses or changes with your physician or an IBCLC.

Frequently asked

What is Pantoprazole used for?

Pantoprazole is evaluated for the following indications with varying evidence strength: NSAID gastropathy prophylaxis (evidence tier A), Gastroesophageal reflux disease (evidence tier A), Peptic ulcer disease (evidence tier A). See the full indication matrix with dosing and citations above on this page.

What are the side effects of Pantoprazole?

Common side effects of Pantoprazole (≥ 1 in 100): Headache, Diarrhea, Nausea, Flatulence, Abdominal pain. See the Safety section for uncommon and serious reactions.

Is Pantoprazole safe during pregnancy?

FDA category B. FDA category B. Safety data in pregnancy are limited, but animal studies have shown no teratogenic effect. Used when clearly indicated.

Is Pantoprazole compatible with breastfeeding?

Who should not take Pantoprazole?

Pantoprazole is contraindicated in: Hypersensitivity to PPIs. Full list in the Safety section.

Mechanism of action

Practical notes

Timing and administration

Special situations

Drug–drug interactions

3 pairs found. Sorted from critical to minor.

Major

Methotrexate

Antimetabolites, folic acid analogues

Mechanism

Proton pump inhibitors block the renal BCRP transporter, reducing methotrexate clearance. At high oncologic doses: risk of severe delayed toxicity.

Symptoms

Mouth ulcers (mucositis), nausea, diarrhoea, hair loss. Blood counts fall: leukocytes, platelets, erythrocytes. Severe cases: fatal pancytopenia, nephrotoxicity.

Management

Sources

FDA: Methotrexate Sodium Tablets prescribing information (2016)

Pair details →

Moderate

Atorvastatin

HMG-CoA reductase inhibitors (statins)

Mechanism

Pantoprazole is the most CYP-neutral PPI. No clinically significant interaction with statins.

Symptoms

No changes.

Management

The combination is acceptable without dose change. Pantoprazole is the preferred PPI in patients on statins and other CYP3A4-dependent drugs.

Sources

FDA: Lipitor (atorvastatin) prescribing information (2017)

Pair details →

Moderate

Cyanocobalamin

Vitamins. Haemopoietic stimulants

Mechanism

Pantoprazole reduces gastric acidity and B12 release from food. With long-term therapy, B12 deficiency risk is reported, similar to other PPIs.

Symptoms

Fatigue, pallor, paraesthesias in hands and feet, gait instability, memory decline. Develops over 2–4 years of unrecognised therapy.

Management

Sources

PubMed: Metformin use and vitamin B12 deficiency: a systematic review and meta-analysis (2020)

Pair details →

Safety

Contraindications

Hypersensitivity to PPIs

Serious adverse effects

Clostridioides difficile-associated diarrhea
Hypomagnesemia with long-term use (over 1 year)
Increased fracture risk with long-term use – hip, wrist, spine
Vitamin B12 deficiency with use over 2 years
Acute interstitial nephritis (rare)

Common adverse effects

Headache
Diarrhea
Nausea
Flatulence
Abdominal pain

PregnancyFDA B

FDA category B. Safety data in pregnancy are limited, but animal studies have shown no teratogenic effect. Used when clearly indicated.

Breastfeeding

Calculate RID Full profile on NIH LactMed ↗

Reference information, not a clinical decision. Discuss feeding pauses or changes with your physician or an IBCLC.

Frequently asked

What is Pantoprazole used for?

What are the side effects of Pantoprazole?

Common side effects of Pantoprazole (≥ 1 in 100): Headache, Diarrhea, Nausea, Flatulence, Abdominal pain. See the Safety section for uncommon and serious reactions.

Is Pantoprazole safe during pregnancy?

FDA category B. FDA category B. Safety data in pregnancy are limited, but animal studies have shown no teratogenic effect. Used when clearly indicated.

Is Pantoprazole compatible with breastfeeding?

Who should not take Pantoprazole?

Pantoprazole is contraindicated in: Hypersensitivity to PPIs. Full list in the Safety section.